Tag:
Doxil
Latest Headlines
Latest Headlines
J&J opens up Doxil rationing on 'limited' new supply
After months of restricting Doxil treatment to current patients, Johnson & Johnson has opened up its rationing program to new ones.
J&J pharma revenues tick upward on new products, overseas sales
Johnson & Johnson's first-quarter sales may have taken a hit, but its prescription drugs business actually grew.
Manufacturing issues continue to undermine J&J earnings
Manufacturing issues that have led to recalls and product shortages continue to be a drag on the earnings of Johnson & Johnson, but the company saw its first quarter profits rise by double digits.
J&J looks for workaround to ease Doxil shortage
The idea is to allow its former contract manufacturer to formulate the cancer drug, and then send it elsewhere for filling and packaging.
J&J considers manufacturing workaround for Doxil
By jumping through some manufacturing hoops, Johnson & Johnson hopes to ease the shortage of its cancer drug Doxil by this fall.
FDA calls on contractors, India to counter Ben Venue drug shortages
A non-FDA approved drug from India and U.S. contract manufacturers will address cancer drug shortages resulting from production and quality problems at Ben Venue Laboratories ' now notorious Ohio...
FDA brings Sun's Doxil copy online to fix shortage
Fresh off its cobbled-together solution to a methotrexate shortage, the FDA says it's sewn up an alternate supply of the scarce cancer drug Doxil . The agency has approved a substitute for the...
Sanofi yanks drug batch on CMO contamination fears
Here's another ripple from the Ben Venue Laboratories splashdown. Sanofi's ( $SNY ) Genzyme unit has recalled a batch of its leukemia drug Fludara because of worries about its sterility. The 9,380
Ben Venue's idled plant triggers 'dire' leukemia-drug shortage
Ben Venue Laboratories has another black eye. We've heard a lot about the ongoing shortages of Johnson & Johnson's ( $JNJ ) cancer treatment Doxil , the supply of which is suffering from...
Little 'oomph' in J&J's results as forecasts fall short
Johnson & Johnson ( $JNJ ) delivered a double whammy with its latest financial announcement: Fourth-quarter earnings dropped by 89%, thanks to litigation and a product recall, and profit forecasts
